AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 73
- Registration Number
- NCT01094093
- Locations
- 🇦🇺
Clinical Medical and Analytical eXcellence (CMAX), Adelaide, Australia
🇦🇺Nucleus Network Limited, Melbourne, Victoria, Australia
🇳🇿Auckland Clinical Studies Ltd, Grafton, New Zealand
A Bioavailability Study Comparing Modified-release Capsules and Immediate Release Capsules in Fed and Fasting Conditions
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2010-08-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 62
- Registration Number
- NCT01092299
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 113505
- Registration Number
- NCT01086319
Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2012-12-20
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT01086813
Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 113505
- Registration Number
- NCT01086306
Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 113505
- Registration Number
- NCT01086293
Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments
Completed
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2010-03-15
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 113505
- Registration Number
- NCT01086280
Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
Completed
- Conditions
- Asthma
- Interventions
- Other: 1Other: 2
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 384
- Registration Number
- NCT01085474
- Locations
- 🇪🇸
Malaga, Malaga, Spain
🇪🇸Research Site, Madrid, Spain
Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Migraine
- Interventions
- Drug: RapimeltDrug: [11C]AZ10419369
- First Posted Date
- 2010-03-11
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT01085123
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Economic Evaluation of Heart Failure Management in Colombian Clinics
Completed
- Conditions
- Heart FailureAsthma
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2010-03-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT01084564